Beam Therapeutics annual net profit margin
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics Net Profit Margin Growth & History (BEAM)
Beam Therapeutics's net profit margin was −57.24% for fiscal 2025.
View full Beam Therapeutics company overviewBeam Therapeutics annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −57.24% | +535.88 pp |
| 2024 | 2024-12-31 | −593.13% | −558.04 pp |
| 2023 | 2023-12-31 | −35.09% | +439.45 pp |
| 2022 | 2022-12-31 | −474.54% | +240.37 pp |
| 2021 | 2021-12-31 | −714.91% | +810085.09 pp |
| 2020 | 2020-12-31 | −810,800.00% | −375655.56 pp |
| 2019 | 2019-12-31 | −435,144.44% | — |
Beam Therapeutics quarterly net profit margin
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −25,036.33% | −23829.88 pp |
| Q1 2026 | 2026-03-31 | −297.18% | +1153.02 pp |
| Q4 2025 | 2025-12-31 | 213.13% | +513.64 pp |
| Q3 2025 | 2025-09-30 | −1,162.38% | −484.92 pp |
| Q2 2025 | 2025-06-30 | −1,206.45% | −433.00 pp |
| Q1 2025 | 2025-03-31 | −1,450.20% | −118.64 pp |
| Q4 2024 | 2024-12-31 | −300.51% | −345.67 pp |
| Q3 2024 | 2024-09-30 | −677.47% | −118.59 pp |
| Q2 2024 | 2024-06-30 | −773.45% | −361.96 pp |
| Q1 2024 | 2024-03-31 | −1,331.57% | −933.10 pp |
| Q4 2023 | 2023-12-31 | 45.16% | +236.55 pp |
| Q3 2023 | 2023-09-30 | −558.88% | +134.68 pp |
| Q2 2023 | 2023-06-30 | −411.49% | +20.59 pp |
| Q1 2023 | 2023-03-31 | −398.46% | +422.39 pp |
| Q4 2022 | 2022-12-31 | −191.39% | −64.69 pp |
| Q3 2022 | 2022-09-30 | −693.56% | +2991.63 pp |
| Q2 2022 | 2022-06-30 | −432.08% | +1270451.25 pp |
| Q1 2022 | 2022-03-31 | −820.85% | +3358512.48 pp |
| Q4 2021 | 2021-12-31 | −126.71% | +1590939.96 pp |
| Q3 2021 | 2021-09-30 | −3,685.19% | +570514.81 pp |
| Q2 2021 | 2021-06-30 | −1,270,883.33% | −700583.33 pp |
| Q1 2021 | 2021-03-31 | −3,359,333.33% | −2851700.00 pp |
| Q4 2020 | 2020-12-31 | −1,591,066.67% | — |
| Q3 2020 | 2020-09-30 | −574,200.00% | −257450.00 pp |
| Q2 2020 | 2020-06-30 | −570,300.00% | −272616.67 pp |
| Q1 2020 | 2020-03-31 | −507,633.33% | — |
| Q3 2019 | 2019-09-30 | −316,750.00% | — |
| Q2 2019 | 2019-06-30 | −297,683.33% | — |
Beam Therapeutics net profit margin trends
Over the last five fiscal years, Beam Therapeutics's net profit margin increased from −810,800.00% to −57.24%, a change of +810742.76 percentage points. The latest reported quarter, Q2 2026, shows −25,036.33%.
About the metric
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
Calculation and source
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Beam Therapeutics source filings ↗Community posts
Beam reports durable protein correction with experimental AATD therapy
Beam Therapeutics ($BEAM) presented updated Phase 1/2 results for BEAM-302, its experimental gene-editing treatment for alpha-1 antitrypsin deficiency. The presentation covered 29 patients given a single dose, with follow-up extending to 18 ...